Overcoming Monocyte Complexity in Pulmonary Fibrosis Progression from Onset to End-Stage
OMEGA aims to identify early mechanisms and therapeutic targets in progressive pulmonary fibrosis by studying monocyte subtypes and interstitial lung abnormalities from early to advanced disease stages.
Projectdetails
Introduction
Progressive pulmonary fibrosis (PF) is a debilitating and incurable disease. Scarring of the lung leads to respiratory failure, and 50% of patients die 3-5 years after diagnosis. Our understanding of the pathophysiology of PF is unfortunately limited to established and advanced stages when the extensive lung scarring is irreversible.
Project Overview
OMEGA is designed to explore new mechanisms underlying PF progression, from early to advanced disease, and propose therapies that timely target the disease before it becomes permanent. Two lines of evidence are at the core of OMEGA:
- I was among the first to show that circulating monocytes are strongly linked to PF pathology. However, which subtypes are important and what roles they play in PF etiology is still unknown.
- Interstitial lung abnormalities (ILA) are the only detectable features characterizing earlier stages of PF and can be identified in people without clinical suspicion of disease. Studying ILA provides the unique opportunity to identify early targets that would prevent progression to PF.
Research Objectives
OMEGA will first provide a detailed phenotype definition of human monocyte subtypes from early to advanced PF.
Second, it will probe mechanistically how and where the monocytes acquire a pathogenic phenotype as they journey from the bone marrow to the blood and differentiate in the fibrotic lung.
Methodology
I will use human and mouse material and state-of-the-art methodology to answer these questions. My current standing ensures direct and ample access to patient samples, clinical data, multi-disciplinary interactions, and a team of consultants/collaborators.
Goals
This collaboration will make it possible to identify how monocytes and their progenitors are involved in the progression of PF, and what pathways we can target as early as the disease starts, and as early as monocytes egress the bone marrow, to end the progression of this deadly disease.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.499.459 |
Totale projectbegroting | € 1.499.459 |
Tijdlijn
Startdatum | 1-2-2025 |
Einddatum | 31-1-2030 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBHpenvoerder
- LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
- KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategiesRewind-MF aims to explore and develop innovative strategies for reversing bone marrow fibrosis in Primary Myelofibrosis, enhancing patient treatment options through advanced biological and computational methods. | ERC Consolid... | € 1.999.313 | 2024 | Details |
Monocyte-to-Macrophage Trajectories After Lung Injury: Spatio-temporal investigation, molecular regulation & functional implications for lung regeneration and immunityThis project aims to elucidate the diverse roles and regulatory mechanisms of inflammatory monocyte-derived macrophages in lung injury and repair, using advanced mouse models and human organoid systems. | ERC Consolid... | € 1.999.863 | 2025 | Details |
Stratified Therapeutic Assessment Platform for Short Telomere related Lung Fibrosis using Patient-Derived iPSCThis project aims to develop a human preclinical model to study telomere shortening in idiopathic pulmonary fibrosis and test gene-targeted mRNA therapies for improved patient outcomes. | ERC Starting... | € 1.499.420 | 2023 | Details |
Immune-stromal crosstalk in inflammation and fibrosis: Exploiting the spatiotemporal dynamics of the OSM-OSMR axis in inflammatory bowel disease to develop novel antifibrotic therapiesThis project aims to investigate the role of oncostatin-M in immune-stromal interactions driving intestinal fibrosis in IBD, with the goal of identifying biomarkers and potential therapies. | ERC Starting... | € 1.499.816 | 2023 | Details |
Mending sex differences: Unravelling the female predominance in pulmonary hypertensionThis project aims to uncover the mechanisms behind the female predominance in pulmonary hypertension to identify new therapeutic targets and develop selective drug delivery methods for improved treatment. | ERC Starting... | € 1.499.999 | 2023 | Details |
Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategies
Rewind-MF aims to explore and develop innovative strategies for reversing bone marrow fibrosis in Primary Myelofibrosis, enhancing patient treatment options through advanced biological and computational methods.
Monocyte-to-Macrophage Trajectories After Lung Injury: Spatio-temporal investigation, molecular regulation & functional implications for lung regeneration and immunity
This project aims to elucidate the diverse roles and regulatory mechanisms of inflammatory monocyte-derived macrophages in lung injury and repair, using advanced mouse models and human organoid systems.
Stratified Therapeutic Assessment Platform for Short Telomere related Lung Fibrosis using Patient-Derived iPSC
This project aims to develop a human preclinical model to study telomere shortening in idiopathic pulmonary fibrosis and test gene-targeted mRNA therapies for improved patient outcomes.
Immune-stromal crosstalk in inflammation and fibrosis: Exploiting the spatiotemporal dynamics of the OSM-OSMR axis in inflammatory bowel disease to develop novel antifibrotic therapies
This project aims to investigate the role of oncostatin-M in immune-stromal interactions driving intestinal fibrosis in IBD, with the goal of identifying biomarkers and potential therapies.
Mending sex differences: Unravelling the female predominance in pulmonary hypertension
This project aims to uncover the mechanisms behind the female predominance in pulmonary hypertension to identify new therapeutic targets and develop selective drug delivery methods for improved treatment.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Targeting OGG1 in Idiopathic Pulmonary FibrosisThe TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch. | EIC Transition | € 2.499.998 | 2023 | Details |
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)Palobiofarma aims to develop PBF-680, a first-in-class adenosine receptor antagonist, to treat COPD, targeting disease progression and seeking €30M for further clinical trials. | EIC Accelerator | € 2.476.106 | 2022 | Details |
Macrophage-based immunotherapy of platinum-resistant ovarian cancerThe MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies. | EIC Transition | € 2.499.998 | 2022 | Details |
Ontwikkeling van liposomen met FOS, SCFA, PUFALiposoma Health ontwikkelt liposomale nutraceuticals met fructo-oligosacchariden en vetzuren om de gezondheid van mensen met een afwijkend microbioom te verbeteren, met focus op Parkinson, depressie en diabetes. | Mkb-innovati... | € 20.000 | 2020 | Details |
Targeting OGG1 in Idiopathic Pulmonary Fibrosis
The TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch.
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)
Palobiofarma aims to develop PBF-680, a first-in-class adenosine receptor antagonist, to treat COPD, targeting disease progression and seeking €30M for further clinical trials.
Macrophage-based immunotherapy of platinum-resistant ovarian cancer
The MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies.
Ontwikkeling van liposomen met FOS, SCFA, PUFA
Liposoma Health ontwikkelt liposomale nutraceuticals met fructo-oligosacchariden en vetzuren om de gezondheid van mensen met een afwijkend microbioom te verbeteren, met focus op Parkinson, depressie en diabetes.